Early access
Sign in
Taking people in ItalyPhase 1

Tests mosunetuzumab or glofitamab with CC-220 or CC-99282 in B-cell non-Hodgkin lymphoma

Tests combined treatments in adults with a type of blood cancer called B-cell non-Hodgkin lymphoma.

Key facts

Who runs it
F. Hoffmann-La Roche AG
Where
Bologna, Brescia, Meldola, Milan, and Pisa, ItalySee the 5 sitesAlso in 1 other country, 6 sites
Registry title
An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.
Status
Recruiting
Phase
Phase 1
People taking part
52 people, planned
Started
23 Apr 2026
Expected to end
7 Mar 2029
Type of study
Interventional
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with B-cell non-Hodgkin lymphoma. It tests mosunetuzumab or glofitamab together with CC-220 and CC-99282.

Age
18 years or older
Sex
All sexes can join

Where in Italy

Also in 1 other country, 6 sites

  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyTaking people
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaBrescia, ItalyTaking people
  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.lMeldola, ItalyTaking people
  • Ospedale San Raffaele S.r.l.Milan, ItalyTaking people
  • Azienda Ospedaliero Universitaria PisanaPisa, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests mosunetuzumab or glofitamab with CC-220 or CC-99282 in B-cell non-Hodgkin lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
20 October 2026